

L Number	Hits	Search Text	DB	Time stamp
1	150	@rlad<19970718 and (((membrane with anchoring) or (transmembrane with sequence)) and antigen same present\$6) and ((514/44 or 435/320.1).CCLS.) and tumor	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/09/06 16:02
7	150	@rlad<19970718 and ((membrane with anchoring) or (transmembrane with sequence)) and (antigen same present\$6) and ((514/44 or 435/320.1).CCLS.) and tumor	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/09/06 16:02
13	3	((papillomavirus with E6) or (papillomavirus with E7)) and (@rlad<19970718 and ((membrane with anchoring) or (transmembrane with sequence)) and (antigen same present\$6) and ((514/44 or 435/320.1).CCLS.) and tumor)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/09/06 16:03
-	378	membrane adj anchoring	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/01/10 16:53
-	378	transmembrane adj sequence	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/01/10 16:53
-	713	(membrane adj anchoring) or (transmembrane adj sequence)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/01/10 16:53
-	124564	antigen (immunogen\$ic polypeptide\$)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/01/10 16:59
-	81714	antigen\$2 (immunogen\$ic adj polypeptide\$)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/01/10 16:56
-	565	((membrane adj anchoring) or (transmembrane adj sequence)) and (antigen\$2 (immunogen\$ic adj polypeptide\$))	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/01/10 16:58
-	593241	@rlad<19970718	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/09/05 19:48
-	657	((membrane adj anchoring) or (transmembrane adj sequence)) and ((immunogen\$ic polypeptide\$) (immunogen\$ic protein\$))	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/01/10 17:03
-	388	@rlad<19970718 and (((membrane adj anchoring) or (transmembrane adj sequence)) and ((immunogen\$ic polypeptide\$) (immunogen\$ic protein\$)))	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/01/10 17:03
-	98	((@rlad<19970718 and (((membrane adj anchoring) or (transmembrane adj sequence)) and ((immunogen\$ic polypeptide\$) (immunogen\$ic protein\$)))) and vaccine	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/01/10 17:02
-	475	((membrane adj anchoring) or (transmembrane adj sequence)) same ((immunogen\$ic polypeptide\$) (immunogen\$ic protein\$))	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/01/10 17:03
-	265	@rlad<19970718 and (((membrane adj anchoring) or (transmembrane adj sequence)) same ((immunogen\$ic polypeptide\$) (immunogen\$ic protein\$)))	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/01/10 17:16
-	65	((@rlad<19970718 and (((membrane adj anchoring) or (transmembrane adj sequence)) same ((immunogen\$ic polypeptide\$) (immunogen\$ic protein\$)))) and vaccine	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/01/10 17:03

-	156	(@rlad<19970718 and (((membrane adj anchoring) or (transmembrane adj sequence)) same ((immunogen\$ic polypeptide\$) (immunogen\$ic protein\$)))) and glycoprotein	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/01/10 17:05
-	0	(measles adj virus adj F) and (@rlad<19970718 and (((membrane adj anchoring) or (transmembrane adj sequence)) same ((immunogen\$ic polypeptide\$) (immunogen\$ic protein\$))))	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/09/05 19:51
-	22	measles adj virus adj F	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/01/10 17:08
-	155	@rlad<19970718 and (((membrane adj anchoring) or (transmembrane adj sequence)) same ((immunogen\$ic polypeptide\$) (immunogen\$ic protein\$))) and chimeric	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/09/05 20:01
-	20	(@rlad<19970718 and (((membrane adj anchoring) or (transmembrane adj sequence)) same ((immunogen\$ic polypeptide\$) (immunogen\$ic protein\$)))) and glycoprotein and (HIV adj env\$5)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/01/10 17:27
-	2136	(immunogen\$ic adj polypeptide\$) (immunogen\$ic adj protein\$)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/01/10 17:30
-	88	((membrane adj anchoring) or (transmembrane adj sequence)) and ((immunogen\$ic adj polypeptide\$) (immunogen\$ic adj protein\$))	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/01/10 17:48
-	1	((membrane adj anchoring) or (transmembrane adj sequence)) same ((immunogen\$ic adj polypeptide\$) (immunogen\$ic adj protein\$))	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/01/10 17:31
-	58	((membrane adj anchoring) or (transmembrane adj sequence)) and ((immunogen\$ic adj polypeptide\$) (immunogen\$ic adj protein\$)) and @rlad<19970718	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/01/10 17:32
-	63	((membrane adj anchoring) or (transmembrane adj sequence)) and ((immunogen\$ic adj polypeptide\$) (immunogen\$ic adj protein\$)) and glycoprotein	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/01/10 17:49
-	13	((membrane adj anchoring) or (transmembrane adj sequence)) and ((immunogen\$ic adj polypeptide\$) (immunogen\$ic adj protein\$)) and glycoprotein and vaccine	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/01/10 18:06
-	6	((membrane adj anchoring) or (transmembrane adj sequence)) and ((immunogen\$ic adj polypeptide\$) (immunogen\$ic adj protein\$)) and (nuclear adj location)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/01/10 18:07
-	120	rabies adj glycoprotein	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/01/10 18:08
-	0	((membrane adj anchoring) or (transmembrane adj sequence)) and ((immunogen\$ic adj polypeptide\$) (immunogen\$ic adj protein\$)) and (rabies adj glycoprotein)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/01/10 18:08
-	17	((immunogen\$ic adj polypeptide\$) (immunogen\$ic adj protein\$)) and (rabies adj glycoprotein)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/09/05 19:38
-	504	chimeric adj \$4peptide\$	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/01/10 18:22

-	16	kieny.in. and tumor	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/09/05 19:45
-	272	papillomavirus with E6	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/09/05 19:47
-	231	(papillomavirus with E6) and tumor	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/09/05 19:47
-	328	papillomavirus with E7	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/09/05 19:47
-	398	(papillomavirus with E6) or (papillomavirus with E7)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/09/06 16:03
-	13555	((514/44 or 435/320.1).CCLS.)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/09/05 19:48
-	98	((papillomavirus with E6) or (papillomavirus with E7)) and ((514/44 or 435/320.1).CCLS.)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/09/05 19:48
-	53	@rlad<19970718 and (((papillomavirus with E6) or (papillomavirus with E7)) and ((514/44 or 435/320.1).CCLS.))	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/09/05 19:49
-	19	((@rlad<19970718 and (((papillomavirus with E6) or (papillomavirus with E7)) and ((514/44 or 435/320.1).CCLS.))) and ((measles with F) or (rabies with glycoprotein) or env)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/09/05 19:53
-	1820	@rlad<19970718 and (((membrane with anchoring) or (transmembrane with sequence)) same ((immunogen\$ic polypeptide\$) (immunogen\$ic protein\$))))	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/09/05 20:06
-	16	((membrane with anchoring) or (transmembrane with sequence)) same (antigen with present\$6)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/09/05 20:09
-	2	@rlad<19970718 and (((membrane with anchoring) or (transmembrane with sequence)) same (antigen with present\$6)) and ((514/44 or 435/320.1).CCLS.)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/09/05 20:09
-	18	((membrane with anchoring) or (transmembrane with sequence)) same antigen same present\$6	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/09/05 20:09
-	3	@rlad<19970718 and (((membrane with anchoring) or (transmembrane with sequence)) same antigen same present\$6) and ((514/44 or 435/320.1).CCLS.)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/09/06 15:59
-	201	@rlad<19970718 and (((membrane with anchoring) or (transmembrane with sequence)) and antigen same present\$6) and ((514/44 or 435/320.1).CCLS.)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/09/06 16:00

heat stable Taq polymerase, sequence specific DNA primers, ATP, CTP, GTP and TTP. Double-stranded DNA is produced when synthesis is complete. This cycle may be repeated many times, resulting in a factorial amplification of the desired DNA.

Detailed Description Text - DETX:

Sequences which encode the above-described anti-tumor agents may also be synthesized, for example, on an Applied Biosystems Inc. DNA synthesizer (e.g., ABI DNA synthesizer model 392 (Foster City, Calif.)).

ant fur
broad
claiming

Detailed Description Text - DETX:

In addition to the anti-tumor agents described above, the present invention also provides anti-tumor agents which comprise a fusion protein of, for example, two or more cytokines, immune modulators, toxins or differentiation factors. Preferred anti-tumor agents in this regard include alpha interferon-Interleukin-2, GM-CSF-IL-4, GM-CSF-IL-2, GM-CSF-IL-3 (see U.S. Pat. Nos. 5,082,927 and 5,108,910), GM-CSF-gamma interferon, and gamma interferon-IL-4. Within a particularly preferred embodiment, the anti-tumor agent is a gamma interferon-Interleukin-2 fusion protein. The construction of these anti-tumor agent(s) may be readily accomplished given the disclosure provided herein. The construction of a particularly preferred anti-tumor agent, gamma interferon-Interleukin-2, is described in more detail below in Example 1F.

Detailed Description Text - DETX:

Within other embodiments of the invention, the anti-tumor agent may further comprise a membrane anchor, and may be constructed, for example, as an anti-tumor agent-membrane anchor fusion protein. Briefly, the membrane anchor aspect of the fusion protein may be selected from a variety of sequences, including, for example, the transmembrane domain of well known molecules. Generally, membrane anchor sequences are regions of a protein that bind the protein to a membrane. Customarily, there are two types of anchor sequences that attach a protein to the outer surface of a cell membrane: (1) transmembrane regions that span the lipid bilayer of the cell membrane, and interact with the hydrophobic center region (proteins containing such regions are referred to integral membrane proteins), and (2) domains which interact with an integral membrane protein or with the polar surface of the membrane (such proteins are referred to as peripheral, or extrinsic, proteins).

Detailed Description Text - DETX:

Membrane anchors for use within the present invention may contain transmembrane domains which span the membrane one or more times. For example, in glycoporphin and guanylyl cyclase, the membrane binding region spans the membrane once, whereas the transmembrane domain of rhodopsin spans the membrane seven times,